Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
2.395
-0.005 (-0.21%)
Oct 16, 2026, 10:04 AM EDT - Market open
Protara Therapeutics Stock Forecast
TARA's stock price has decreased by -55.22% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 8 analysts polled by S&P Global, Protara Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $25.71. The average 1-year stock price forecast is 973.49% higher than the current stock price, while the lowest is $20 (+735.07%) and the highest is $30 (+1,152.61%).
Price Target: $25.71 (+973.49%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Protara Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $27 | Buy | Maintains | $27 | +1,027.35% | Sep 21, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $25 | Buy | Maintains | $25 | +943.84% | Aug 12, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $22 → $20 | Buy | Reiterates | $22 → $20 | +735.07% | Aug 11, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 1, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $24 | Buy | Maintains | $24 | +902.09% | May 21, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.00M
EPS This Year
-1.39
from -1.34
EPS Next Year
-1.69
from -1.39
EPS and Forward PE are based on non-GAAP adjusted numbers.